Antagonism of detomidine sedation in the horse using intravenous tolazoline or atipamezole.

Summary

# Editorial Summary: Antagonism of detomidine sedation in the horse using intravenous tolazoline or atipamezole Hubbell and Muir (2006) investigated whether alpha-2 antagonists could effectively reverse detomidine sedation, a clinically relevant question given that shortening sedation duration would enhance safety during routine procedures. Six horses received detomidine (0.02 mg/kg IV), followed 25 minutes later by one of four treatments in a randomised, placebo-controlled, double-blind design: saline placebo, atipamezole at either 0.05 or 0.1 mg/kg IV, or tolazoline at 4.0 mg/kg IV, with sedation, muscle relaxation and ataxia scored at multiple time points alongside objective assessment of locomotor recovery using an obstacle course. Both antagonists produced incomplete but clinically meaningful reversal of detomidine's effects, significantly accelerating the time course to recovery compared with saline controls, though neither achieved complete antagonism of all sedative parameters. For practitioners, these findings suggest that either atipamezole or tolazoline offers a practical method to hasten recovery from detomidine sedation when procedures need to be concluded more quickly; however, the partial nature of reversal means horses should still be monitored carefully and not assumed to be fully alert or coordinated immediately post-antagonism.

Read the full abstract on PubMed

Key Findings

• •Both atipamezole (0.05 and 0.1 mg/kg) and tolazoline (4.0 mg/kg) incompletely antagonised detomidine sedation but shortened recovery time
• •Single bolus administration of either antagonist produced only partial reversal of detomidine's sedative effects
• •Antagonists may be useful for minimising residual detomidine sedation in clinical practice

Conditions Studied